Applied Therapeutics (APLT) Competitors $0.49 +0.00 (+0.16%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. PVLA, ATXS, SLRN, ITOS, CMPX, ALMS, MNPR, GLUE, CDTX, and AARDShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Palvella Therapeutics (PVLA), Astria Therapeutics (ATXS), Acelyrin (SLRN), iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Alumis (ALMS), Monopar Therapeutics (MNPR), Monte Rosa Therapeutics (GLUE), Cidara Therapeutics (CDTX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Palvella Therapeutics Astria Therapeutics Acelyrin iTeos Therapeutics Compass Therapeutics Alumis Monopar Therapeutics Monte Rosa Therapeutics Cidara Therapeutics Aardvark Therapeutics Palvella Therapeutics (NASDAQ:PVLA) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Which has more risk and volatility, PVLA or APLT? Palvella Therapeutics has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Does the MarketBeat Community believe in PVLA or APLT? Applied Therapeutics received 66 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 57.14% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformPalvella TherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesApplied TherapeuticsOutperform Votes8057.14% Underperform Votes6042.86% Is PVLA or APLT more profitable? Palvella Therapeutics' return on equity of -80.93% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -80.93% -59.55% Applied Therapeutics N/A -260.75%-76.04% Do analysts prefer PVLA or APLT? Palvella Therapeutics currently has a consensus target price of $44.43, suggesting a potential upside of 104.74%. Applied Therapeutics has a consensus target price of $6.10, suggesting a potential upside of 1,157.21%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor PVLA or APLT? In the previous week, Palvella Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 8 mentions for Palvella Therapeutics and 6 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 1.09 beat Palvella Therapeutics' score of 0.76 indicating that Applied Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Applied Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, PVLA or APLT? Palvella Therapeutics has higher revenue and earnings than Applied Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M5.60-$24.54M-$12.10-1.79Applied Therapeutics$455K150.97-$119.76M-$0.95-0.51 Do insiders and institutionals have more ownership in PVLA or APLT? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryPalvella Therapeutics and Applied Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.69M$6.24B$5.22B$8.47BDividend YieldN/A3.01%4.99%4.19%P/E Ratio-0.308.6526.4919.71Price / Sales150.97268.83398.79120.61Price / CashN/A65.8538.3134.62Price / Book-2.436.266.684.51Net Income-$119.76M$143.73M$3.22B$247.94M7 Day Performance17.77%-0.38%0.08%3.40%1 Month Performance47.84%4.55%5.42%11.07%1 Year Performance-88.97%-7.57%13.21%5.78% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.0236 of 5 stars$0.49+0.2%$6.10+1,155.1%-89.5%$68.95M$455,000.00-0.3030Analyst ForecastPositive NewsGap UpPVLAPalvella Therapeutics3.6245 of 5 stars$21.72-1.6%$44.43+104.6%N/A$239.85M$42.81M-1.80N/AEarnings ReportATXSAstria Therapeutics2.2981 of 5 stars$4.25-3.8%$30.00+605.9%-58.2%$239.84MN/A-2.0330Earnings ReportAnalyst ForecastSLRNAcelyrin2.7506 of 5 stars$2.37-2.1%$9.60+305.1%-56.7%$239.15MN/A-0.96135Earnings ReportPositive NewsITOSiTeos Therapeutics2.8287 of 5 stars$6.24-3.1%$25.50+308.7%-54.5%$238.83M$35M-1.9890Analyst DowngradeNews CoverageCMPXCompass Therapeutics3.7967 of 5 stars$1.73-2.0%$13.38+675.4%+23.8%$238.54M$850,000.00-4.6620Earnings ReportAnalyst RevisionALMSAlumis2.61 of 5 stars$5.01+4.6%$25.86+416.1%N/A$236.58MN/A0.00N/AEarnings ReportPositive NewsGap UpMNPRMonopar Therapeutics2.9567 of 5 stars$38.67-0.3%$55.33+43.1%+1,040.1%$236.47MN/A-19.6310Earnings ReportGap DownGLUEMonte Rosa Therapeutics2.1873 of 5 stars$3.83-0.5%$15.50+304.7%-26.0%$235.58M$75.62M-2.0990Earnings ReportAnalyst RevisionNews CoverageCDTXCidara Therapeutics4.4389 of 5 stars$18.77-1.1%$39.14+108.5%+47.5%$235.51M$1.28M-0.7490Earnings ReportAARDAardvark TherapeuticsN/A$10.68+0.5%$31.50+194.9%N/A$231.71MN/A0.0018Earnings ReportNews CoverageGap UpTrading Halted Related Companies and Tools Related Companies Palvella Therapeutics Alternatives Astria Therapeutics Alternatives Acelyrin Alternatives iTeos Therapeutics Alternatives Compass Therapeutics Alternatives Alumis Alternatives Monopar Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Cidara Therapeutics Alternatives Aardvark Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
